> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Invega Not Withdrawn Due to Safety/Efficacy
- URL: https://www.fdaweb.com/invega-not-withdrawn-due-to-safety-efficacy/
- Published: 2024-06-24T12:00:00.000Z
- Updated: 2026-09-14T14:34:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157236

*Federal Register* notice: FDA has determined that Janssen Pharmaceuticals’ Invega (paliperidone) extended-release tablet, 1.5 mg, was not withdrawn from sale due to safety or effectiveness reasons. The determination will allow FDA to continue to approve ANDAs that referenced the product as long as they meet relevant legal and regulatory requirements. Paliperidone is indicated for treating schizophrenia and schizoaffective disorder. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-06-24/pdf/2024-13803.pdf?ref=fdaweb.com).